ABT vs IBTA · P/E 25, rev $44.33B vs rev $342.4M
Abbott Laboratories (ABT) versus Ibotta, Inc. (IBTA) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Ibotta, Inc. (IBTA) is a software - application company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported IBTA revenue for 2025-12-31 was $342.4M. Net income was $3.6M. Revenue was down 6.8% from 2024-12-31 to 2025-12-31. IBTA currently screens at market cap $764.6M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. IBTA currently screens at market cap $764.6M.
Not investment advice. Open the ABT and IBTA stock pages for the full models.
Not investment advice.